# AFQ056 for Language Learning in Children With FXS

> **NCT02920892** · PHASE2 · COMPLETED · sponsor: **Elizabeth Berry-Kravis** · enrollment: 110 (actual)

## Conditions studied

- Fragile X Syndrome

## Interventions

- **DRUG:** AFQ056
- **DRUG:** Placebo
- **OTHER:** Language Intervention

## Key facts

- **NCT ID:** NCT02920892
- **Lead sponsor:** Elizabeth Berry-Kravis
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-17
- **Primary completion:** 2022-05-17
- **Final completion:** 2022-05-17
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2023-10-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02920892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02920892, "AFQ056 for Language Learning in Children With FXS". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02920892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*